Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease.

Blood advances·2026

Same author

Early Restrictive vs Liberal Oxygen for Trauma Patients: The TRAUMOX2 Randomized Clinical Trial.

JAMA·2024

Same author

Commentary on the ANNEXA-I trial from the guideline group of the European Society of Anaesthesiology and Intensive Care (ESAIC) on the reversal of direct oral anticoagulants in patients with life threatening bleeding.

European journal of anaesthesiology·2024

Same author

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders.

Nature cardiovascular research·2024

Same author

European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Chapter 5: Mechanical prophylaxis.

European journal of anaesthesiology·2024

Same author

Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding.

European journal of anaesthesiology·2024

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Published on: April 29, 2007

Fibrinogen concentrate--a potential universal hemostatic agent.

Christian Fenger-Eriksen¹, Jørgen Ingerslev, Benny Sørensen

¹Aarhus University Hospital, Department of Anaesthesiology, Skejby, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. chfen@dadlnet.dk

Expert Opinion on Biological Therapy

|August 4, 2009

Summary

Early administration of pasteurized fibrinogen concentrate is crucial for patients with acquired fibrinogen deficiency during massive bleeding. This treatment is effective and well-tolerated, with a low risk of adverse events.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Related Experiment Videos

Last Updated: Jun 21, 2026

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Published on: April 29, 2007

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Area of Science:

Hematology
Transfusion Medicine
Pharmacology

Background:

Human fibrinogen concentrates are established therapies for congenital fibrinogen disorders.
Emerging evidence highlights fibrinogen's critical role in hemostasis, especially in acquired deficiencies during massive hemorrhage.
Early intervention with fibrinogen concentrate may be beneficial in managing acquired fibrinogen deficiency.

Purpose of the Study:

To review pasteurized fibrinogen concentrate, focusing on its characteristics, effects, and clinical use.
To discuss product details, pharmacodynamics, pharmacokinetics, monitoring, dosing, efficacy, and safety.
To outline future clinical and laboratory research directions for fibrinogen.

Main Methods:

Literature review and synthesis of existing data on pasteurized fibrinogen concentrate.
Analysis of pharmacokinetic and pharmacodynamic properties.
Evaluation of clinical efficacy and safety data from studies and observations.

Main Results:

Pasteurized fibrinogen concentrate has a half-life of 2.7 days in patients with congenital deficiency.
In vivo recovery rates range from 60% to 109% for both congenital and acquired deficiencies.
Administration is reportedly efficacious in congenital deficiency and shows promise in acquired deficiency.

Conclusions:

Acquired fibrinogen deficiency is an early complication in severe bleeding.
Early fibrinogen substitution may benefit patients with critical traumatic and surgical bleeding.
Pasteurized fibrinogen concentrate is well-tolerated with a low incidence of thrombo-embolic events.